{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-096389","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.340465+00:00","generated_at":"2026-06-03T22:51:10.725669+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aileron reports Q4 net loss $7.3M; expects LTI-03 topline results in Q3 2024","bullets":["Net loss Q4 2023 $7.3M ($1.54 per share) vs $4.5M ($1.00) in Q4 2022; FY 2023 net loss $3.42 per share vs $6.02.","Cash, cash equivalents and investments $17.3M at Dec 31, 2023; runway into Q4 2024.","Completed merger with Lung Therapeutics in Oct 2023; raised ~$18M in private placement.","Appointed Brian Windsor as President and CEO in March 2024 (ex-CEO of Lung).","LTI-03 Phase 1b topline results in IPF expected Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-096389","json":"https://secwatch.observer/filing/0001193125-24-096389.json","markdown":"https://secwatch.observer/filing/0001193125-24-096389.md","text":"https://secwatch.observer/filing/0001193125-24-096389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/0001193125-24-096389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/d817402d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:51:10.725669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e787fcdb2bbbb8298eeca84697aeb44d3f42621d","claim":"Rein Therapeutics, Inc. reported full year ended December 31, 2023 results: EPS $3.42 per share.","evidence_excerpt":"The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/0001193125-24-096389-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"EPS","value":"$3.42 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fdd6646888f4e52f129f4aac6438f691e3b3ba03","claim":"Rein Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income $7.3 million, EPS $1.54 per share.","evidence_excerpt":"Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022. The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/0001193125-24-096389-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Net income","value":"$7.3 million"},{"label":"EPS","value":"$1.54 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}